Completed PHASE3 INTERVENTIONAL 2-arm NCT01566604

Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (GLOW7)

A 26-week Treatment, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 (50 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease

Sponsor: Novartis Pharmaceuticals

Conditions Chronic Obstructive Pulmonary Disease (COPD)

Interventions NVA237 Placebo

Updated 6 times since 2017 Last updated: Jul 16, 2014 Started: Mar 31, 2012 Primary completion: Jun 30, 2013 Completion: Jun 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Chronic Obstructive Pulmonary Disease (COPD), this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 6 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Bulacan, Philippines , Changsha, China , Chengdu, China , Chongqing, China , Coimbatore, India , Daejeon, South Korea , Dehli, India , Guangzhou, China , Incheon, South Korea and 13 more locations